Page last updated: 2024-11-11

zy 17617b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CGS 9343B: calmodulin antagonist; structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6450522
SCHEMBL ID1649784
MeSH IDM0147998

Synonyms (34)

Synonym
HMS3268F12
kw-5617
cgs-9343b
zaldaride maleate
zy-17617b
2h-benzimidazol-2-one, 1,3-dihydro-1-(1-((4-methyl-4h,6h-pyrrolo(1,2-a)(4,1)benzoxazepin-4-yl)methyl)-4-piperidinyl)-, (z)-2-butenedioate (1:1)
cgs 9343b
zy 17617b
kw 5617
unii-k7sg01p7nj
109826-27-9
k7sg01p7nj ,
1,3-dihydro-1-[1-[(4-methyl-4h,6h-pyrrolo[1,2-a][4,1]- benzoxazepin-4-yl)methyl]-4-piperidinyl]-2h-benzimidazol-2-one maleate
smr004701642
MLS006010639
SCHEMBL1649784
1-[1-(4-methyl-4h,6h-5-oxa-10b-aza-benzo[e]azulen-4-ylmethyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one maleate
1,3-dihydro-1-[1-[(4-methyl-4h,6h-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl)methyl]-4-piperidinyl]-2h-benzimidazol-2-one maleate
AKOS024457009
cgs-9343b, >=98% (hplc), powder
1-(1-((4-methyl-4h,6h-benzo[e]pyrrolo[2,1-c][1,4]oxazepin-4-yl)methyl)piperidin-4-yl)-1,3-dihydro-2h-benzo[d]imidazol-2-one maleate
HMS3677A04
HY-105118A
HMS3413A04
CS-0025049
Q27282060
MS-30004
(z)-but-2-enedioic acid;3-[1-[(4-methyl-6h-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl)methyl]piperidin-4-yl]-1h-benzimidazol-2-one
cgs-9434b
zaldaride maleate [mart.]
(+/-)-1-(1-((4-methyl-4h,6h-pyrrolo(1,2-a)(4,1)benzoxazepin-4-yl)methyl)-4-piperidyl)-2-benzimidazolinone maleate
zaldaride maleate [mi]
1,3-dihydro-1-(1-((4-methyl-4h,6h-pyrrolo(1,2-a)(4,1)benzoxazepin-4-yl)methyl)-4-piperidinyl)-2h-benzimidazol-2-one maleate
E98739

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Cadmium (Cd), the heavy metal, is toxic to the placenta."( Toxicity of cadmium in human trophoblast cells (JAr choriocarcinoma): role of calmodulin and the calmodulin inhibitor, zaldaride maleate.
Keng, PC; Miller, RK; Powlin, SS, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
"(1) Zaldaride 20 mg four times daily, (2) zaldaride 2 x 20 mg as initial loading dose followed by three doses of 20 mg on the first day and four doses of 20 mg on the second day, (3) loperamide 2 x 2 mg loading dose following by a flexible dosage of 2 mg after each unformed stool (maximum of 16 mg daily), (4) placebo."( Treatment of travellers' diarrhoea: zaldaride compared with loperamide and placebo.
el-Etr, S; Gyurech, D; Kilpatrick, ME; Mathewson, JT; Mourad, AS; Murphy, JR; Oyofo, BA; Schick, MT; Silberschmidt, G; Steffen, R, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (7.81)18.7374
1990's43 (67.19)18.2507
2000's14 (21.88)29.6817
2010's2 (3.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.06 (24.57)
Research Supply Index4.25 (2.92)
Research Growth Index5.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (4.55%)5.53%
Reviews3 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other60 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]